CasNo.162401-32-3,Roflumilast,(162401-32-3) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 99%
Payment Terms : T/T

Keywords

Roflumilast 162401-32-3 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

Quick Details

Appearance:White crystalline powder
Application:Uses of Roflumilast: It has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstr
PackAge:25kg/ drum 1kg/bag or 10mg/ drum
ProductionCapacity:2000|Metric Ton|Month
Storage:Store in cool, dry, Storage Temp: 2-8°C
Transportation:Store in cool, dry, Storage Temp: 2-8°C Keep away from any acid substance。

Superiority:

Union Pharmpro Co., Ltd is in business of raw materials of health industrial for nearly 14

years. Union Pharmpro is now a united group of three companies( Watson Industries, Yasen

Biological Technology co., Ltd),with it’s headquarters in China and USA is dedicated to the

production and distribution of ingredients to the food,dietary supplement,sports supplement,

cosmetic, pharmaceutical and veterinary industries.

Details:

Name:Roflumilast

CAS No:162401-32-3

Appearance:White to tawny crystalline powder

Molecular Formula:C17H14Cl2F2N2O3

Molecular Weight:403.21

Storage Temp:Refrigerator

Purity:99%,mim

Assay Method:HPLC

Melting Point:158 °C

Roflumilast is oral tablet for daily once. It should be used with other bronchodilators. It is suitable for adult patients with a history of frequent exacerbation of chronic bronchitis and related severe COPD. And it can be used as maintenance therapy.

The indications are: severe COPD patients with cough and phlegm that associated with bronchitis.

The treatment guidelines of roflumilast approved by the US Food and Drug Administration (FDA) shows that its potential menal health risks include changes of mood, thinking or behavior and unexplained weight loss. Roflumilast is not expected to use in other symptoms of COPD, including emphysema treatment. Roflumilast cannot be used in the treatment of sudden breathing problems (acute bronchospasm), and it is not recommended for patients 18 years of age. Major adverse events that are reported include diarrhea, nausea, headache, insomnia, back pain, poor appetite and dizziness.

Quality Control System

We do strict quality control in whole production process. All unqualified products are rejecting before shipping.